TY - JOUR
T1 - Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration
AU - Major, James C.
AU - Wykoff, Charles C.
AU - Croft, Daniel E.
AU - Wang, Rui
AU - Mariani, Angeline F.
AU - Lehmann, Anna E.
AU - Brown, David M.
PY - 2015/10
Y1 - 2015/10
N2 - Objective Assess the efficacy of intravitreal aflibercept on pigment epithelial detachments (PED) associated with previously treated patients with neovascular age-related macular degeneration (AMD). Design Retrospective study. Participants Sixty eyes. Methods Patients with persistent PED who were treated with intravitreal aflibercept (2.0 mg) with ≥2 previous injections of bevacizumab (1.25 mg) or ranibizumab (0.5 mg) were analyzed. Results Mean number of prior injections was 24.8 during a mean of 32 months of management (range 3-77 months). Baseline mean PED height was 258 μm (range 80-687 μm), which decreased at 1, 6, and 12 months upon switching to aflibercept to 226 μm (-14%, range 34-701 μm), 215 μm (-18%, range 0-666 μm), and 208 μm (-22%, range 0-752 μm), respectively. The majority of eyes experienced a decrease in PED height after switching to aflibercept: 50/58 (86%), 38/47 (81%), and 37/47 (79%) at months 1, 6, and 12, respectively. Reduction in PED height was weakly correlated with improved visual acuity (R2 = 0.11). Conclusions Intravitreal aflibercept resulted in significant reduction in PED height in previously treated eyes with neovascular AMD.
AB - Objective Assess the efficacy of intravitreal aflibercept on pigment epithelial detachments (PED) associated with previously treated patients with neovascular age-related macular degeneration (AMD). Design Retrospective study. Participants Sixty eyes. Methods Patients with persistent PED who were treated with intravitreal aflibercept (2.0 mg) with ≥2 previous injections of bevacizumab (1.25 mg) or ranibizumab (0.5 mg) were analyzed. Results Mean number of prior injections was 24.8 during a mean of 32 months of management (range 3-77 months). Baseline mean PED height was 258 μm (range 80-687 μm), which decreased at 1, 6, and 12 months upon switching to aflibercept to 226 μm (-14%, range 34-701 μm), 215 μm (-18%, range 0-666 μm), and 208 μm (-22%, range 0-752 μm), respectively. The majority of eyes experienced a decrease in PED height after switching to aflibercept: 50/58 (86%), 38/47 (81%), and 37/47 (79%) at months 1, 6, and 12, respectively. Reduction in PED height was weakly correlated with improved visual acuity (R2 = 0.11). Conclusions Intravitreal aflibercept resulted in significant reduction in PED height in previously treated eyes with neovascular AMD.
UR - http://www.scopus.com/inward/record.url?scp=84944173680&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944173680&partnerID=8YFLogxK
U2 - 10.1016/j.jcjo.2014.12.012
DO - 10.1016/j.jcjo.2014.12.012
M3 - Article
C2 - 26455973
AN - SCOPUS:84944173680
SN - 0008-4182
VL - 50
SP - 373
EP - 377
JO - Canadian Journal of Ophthalmology
JF - Canadian Journal of Ophthalmology
IS - 5
M1 - 715
ER -